Literature DB >> 11718498

Extended-spectrum beta-lactamases: epidemiology, detection, and treatment.

S Nathisuwan1, D S Burgess, J S Lewis.   

Abstract

Extended-spectrum beta-lactamases (ESBLs) are extremely broad spectrum beta-lactamase enzymes found in a variety of Enterobacteriaceae. Most strains producing these beta-lactamases are Klebsiella pneumoniae, other Klebsiella species (i.e., K. oxytoca), and Escherichia coli. When producing these enzymes, organisms become highly effective at inactivating various beta-lactam antibiotics. In addition, ESBL-producing bacteria are frequently resistant to many classes of antibiotics, resulting in difficult-to-treat infections. Other problems due to ESBL-producing bacteria are difficulty in detecting the presence of ESBLs, limited treatment options, and deleterious impact on clinical outcomes. Clinicians should be familiar with the clinical significance of these enzymes and potential strategies for dealing with this growing problem.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11718498     DOI: 10.1592/phco.21.11.920.34529

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  30 in total

1.  Klebsiella oxytoca bacteremia causing septic shock in recipients of hematopoietic stem cell transplant: Two case reports.

Authors:  Khalid A Al-Anazi; Asma M Al-Jasser; Hazza A Al-Zahrani; Naem Chaudhri; Fahad I Al-Mohareb
Journal:  Cases J       Date:  2008-09-18

2.  The potential of selected South African plants with anti-Klebsiella activity for the treatment and prevention of ankylosing spondylitis.

Authors:  I E Cock; S F van Vuuren
Journal:  Inflammopharmacology       Date:  2014-11-21       Impact factor: 4.473

3.  Risk factors for and outcomes associated with clinical isolates of Escherichia coli and Klebsiella species resistant to extended-spectrum cephalosporins among patients admitted to Canadian hospitals.

Authors:  Marianna Ofner-Agostini; Andrew Simor; Michael Mulvey; Alison McGeer; Zahir Hirji; Melissa McCracken; Denise Gravel; David Boyd; Elizabeth Bryce
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

4.  Prevalence and antibiogram of Extended Spectrum β-Lactamase (ESBL) producing Gram negative bacilli and further molecular characterization of ESBL producing Escherichia coli and Klebsiella spp.

Authors:  Meeta Sharma; Sati Pathak; Preeti Srivastava
Journal:  J Clin Diagn Res       Date:  2013-10-05

Review 5.  Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.

Authors:  Felipe Francisco Tuon; Jaime L Rocha; Marcelo R Formigoni-Pinto
Journal:  Infection       Date:  2017-11-07       Impact factor: 3.553

6.  Advances in management of urinary tract infections.

Authors:  Baldev S Prajapati; Rajal B Prajapati; Panna S Patel
Journal:  Indian J Pediatr       Date:  2008-09-04       Impact factor: 1.967

7.  Prevalence of Extended-spectrum β-Lactamases-producing Escherichia coli from Hospitals in Khartoum State, Sudan.

Authors:  Mutasim E Ibrahim; Naser E Bilal; Magzoub A Magzoub; Mohamed E Hamid
Journal:  Oman Med J       Date:  2013-03

8.  The aetiology of the bloodstream infections in the patients who presented to a tertiary care teaching hospital in kathmandu, Nepal.

Authors:  Santwana Pandey; Shahid Raza; Chandra Prakash Bhatta
Journal:  J Clin Diagn Res       Date:  2013-04-01

9.  Ambler class A extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. in Canadian hospitals.

Authors:  Michael R Mulvey; Elizabeth Bryce; David Boyd; Marianna Ofner-Agostini; Sara Christianson; Andrew E Simor; Shirley Paton
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

10.  Detection of extended spectrum β-lactamase in Pseudomonas spp. isolated from two tertiary care hospitals in Bangladesh.

Authors:  Shahanara Begum; Md Abdus Salam; Kh Faisal Alam; Nurjahan Begum; Pervez Hassan; Jalaluddin Ashraful Haq
Journal:  BMC Res Notes       Date:  2013-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.